ABSTRACT. We analyzed by means of immunoblot technique the patterns of antibodies binding to polypeptides of Borrelia burgdorferi B31 in the sera of 21 children with different stages of Lyme disease. All sera but one recognized the flagellar protein 41 kD and all but two the 83-kD protein. The number of proteins recognized rose from clinical stage I to stage 111. The polypeptides of the mol wt 55 and 31 kD were exclusively bound by IgM and the proteins 66, 58, 39, and 36 kD exclusively by IgG. Based on the number of proteins visualized by single sera, IgM was the predominant isotype in stages I and I1 peaking in stage 11, whereas in stage I11 IgG predominated. Considering the number of proteins recognized and the corresponding antibody isotype, a serologic differentiation between the three stages of the disease is feasible: within stage I and within stage I11 patients with different clinical signs had distinct antibody patterns. No clearcut pattern could be discriminated in stage I1 for patients with different settings. Immunoblotting yields a possible distinction between active infection and serological scar by the detection of specific antibody patterns. (Pediatr Res 26:377-382, 1989) 
of dissemination with cardiac disease, migratory musculoskeletal pain, or neurologic involvement, i.e. meningitis, seventh nerve palsy, or polyradiculitis.
Stage III. Weeks to years later, a few patients may develop arthritis, which untreated may become chronic with pannus formation and even with destructive erosion of cartilage and bone. Untreated neurologic syndromes may also become chronic or intermittently recurring. For unknown reasons every sign or finding can occur in isolation (2) . Similarly, ACA, a dermatologic condition with erythema, shift of pigmentation, and frail skin, is a sign of the third stage of the illness. These lesions are mostly localized on the extensor surface of one extremity of adults after the third decade (3), but we observed them also in children (4) . First and second stage manifestations may resolve spontaneously. Because of the potential progression to chronic disturbances, however, antibiotic treatment is recommended in all stages, in children preferably with penicillin, in adults also with tetracyclines (2) . Recently, successful treatment of late Lyme disease with cephalosporins has also been reported (5) .
A history of tick bite and/or previous or actual ECM strongly suggests the diagnosis of Lyme disease. It should immediately be confirmed by determination of antibodies against B. burgdorferi (6) (7) (8) (9) . In atypical patients serology is essential, with the reservation that a positive titer to B. burgdorferi may represent a "serologic scar" due to a previous infection without actual interest.
The purpose of the present study was 1 ) to analyze the antibody response to B. burgdorferi antigens in children with different manifestations of Lyme disease by means of the immunoblot technique, 2) to investigate possible correlations of the antibody patterns to the stage of the disease, and 3 ) to evaluate the potential of immunoblotting to distinguish between active infection and serological scar.
MATERIALS AND METHODS

Patients.
All patients treated at the University Children's Hospital of Zurich because of Lyme disease during the period from June 1985 to December 1987 were included in the study. The clinical data were gathered by chart review. Sera collected before treatment were stored at -70°C.
Materials. All chemicals as well as the instruments for electrophoresis and immunoblotting were purchased from LKB (Diibendorf, Switzerland) with the following exceptions: 4-chloro-1 -naphthol from Merck (Zurich, Switzerland), antisera for immunofluorescence assay from Behring (Marburg, FRG) and for immunoblotting from Dakopatts (IG-Instruments, Zurich, Switzerland), mol wt markers and NC paper from BioRad (Glatt-brugg, Switzerland), and human IgG from Schweizerisches Serum & Impfinstitut (Bern, Switzerland). Antigen preparation. B. burgdorferi B3 1 (ATCC 352 10) was used for all antigen preparations. The spirochete was cultured in Barbour, Stonner, Kelly medium I (10) for 4-6 d at 37°C until a final density of at least 20 organisms per 400-fold magnification field was reached. Cells were harvested by centrifugation at 10 000 x g for 30 min at 4°C.
ZFA. Global Ig-IFA was performed by standard methods, as previously described (7) . In brief, the harvested B. burgdorferi cells were three times resuspended in PBS and centrifuged at 10 000 x g for 30 min at 4°C. The pellet was resuspended in PBS to a final concentration of 15-20 cells per 400-fold magnification field. Ten pL of the suspension were pipetted onto each of 10 circles of a slide, air dried, and frozen at -75°C. Fixation with acetone was done before use. Twenty-five pL of the patient's serum dilutions (2-fold steps beginning with 1:32) in PBS were incubated at 37°C for 30 min. After washing three times with PBS and air drying, the slides were stained with a 1:60 dilution of fluorescein-isothiocyanate-labeled goat antihuman y-globulin fraction, incubated for 30 min, washed twice in PBS, and finally rinsed with deionized water. Titers rl:64 were regarded as significantly elevated (compared with 100 sera collected from healthy blood donors).
Electrophoresu. SDS-PAGE was performed in a modified version of the method described by Laemmli (1 1). Pelleted spirochetes were resuspended three times in cold PBS with 5 mM MgC12 and centrifuged for 30 min at 4°C. The washed cells were resuspended in deionized water to reach a protein concentration of 0.5 g/L, measured according to the method of Lowry et al. (12) . Electrophoresis of the spirochetal protein (0.5 pg/mm gel) was done on a 10% acrylamide gel (18 cm plate, 1.5 mm gel thickness; 30:0.8 acry1amide:bisacrylamide) with Z-mercaptoethan01 as reducing agent in the sample buffer. Two gels were run simultaneously in one chamber at a current of 60 mA at 12°C for approximately 5 h until a marker dye had traversed 10 cm of gel.
Separated polypeptides on the gels were stained with Coomassie Brilliant Blue R-250 or transferred to NC paper in a modified version of the method of Towbin et al. (13) using a Multiphor Novablot electrophoresis transfer unit (LKB). The transfer time was 1 h at a current of 150 mA. To assess the efficiency of transfer, one longitudinal strip was cut from the NC sheet and stained with amido black and compared to immunoblots. Prestained molecular weight markers were phosphorylase b (79 400), BSA (66 200), ovalbumin (42 622), carbonic anhydrase (3 1 OOO), soybean trypsin inhibitor (2 1 500), and lysozyme ( 14 400).
Zmmunoblotting and detection of antigens. The NC paper containing transferred polypeptides was soaked for 1 h at room temperature in 2% BSA in TBS to saturate nonspecific proteinbinding sites. The NC sheets were dried between filter paper and stortll . t 4°C. The MC was cul Into 4-mrn wide strips representing individual lanes from tlic gel. The strips wcrc incubated individually witli patient scra diluted 1:100 in TBS-0.05-Twecn 20 overnight at room temperature on a rocking table. After washing thc strips three timcs with TBS-0.05-Tween 20, they were incubated for 1 1. 1 at room tcmperaturc witli a 1:200 dilution of horseradish peroxidase-conjugated goat antibody to human ychain. AAcr three more washings the NC were stained with 4-chloro-1-naphthol for 20 min. Finally, thc staining was stopped by washing the strips once with TBS and twice with deionized watcr. Control samples included serum from five normal individuals and from two patients with syphilis, and in addition thc conjugate alonc.
To identify spirochetal proteins, the mAb H5332 which reacts with the outer membrane protein subunit of B. hurgdor/krr B3 I (3 1 000) (14) and 149724 which binds to B. hurgdor/hri flagellin (4 1 000) (1 5) wcrc uscd (both kindly provided by A. G. Barbour, San Antonio, TX).
Rheumatoid factor. (Figs. 1 and 2) .
Sera of the four patients with stage I (patients 1-4) contained Ig binding to three to 10 polypeptides. All sera had IgM reacting with two to seven polypeptides and IgG reacting with one to six. The 41-kD protein was bound by IgG from all sera and by IgM from all but one. Both patients with ECM had in common the binding of IgM to the 31-kD polypeptide and of IgG to the 29-kD protein, a pattern not found in the two children suffering from headaches.
The sera of the nine patients assigned to stage I1 (patients 5-13) reacted with four to 10 proteins, IgM with four to seven, and IgG to as many as six. Compared with stage I, six additional proteins were visualized. Furthermore, in stage 11, IgM bound to more proteins per serum than in stage I (mean 5.7 bands versus 4.3), whereas the number of bands per serum visualized by IgG did not differ (mean 2.9 versus 3). A constant finding in all sera was the binding of the 83-kD protein by IgM and/or IgG and in all sera but one the reaction with the 41-kD polypeptide. The patient with polyneuropathy was the only one with no antibodies against the 41-kD protein and both patients with paresthesia were the only ones with IgM but no IgG reacting with this protein. Moreover, these latter two patients and the one with meningitis were unique with IgM binding to both proteins 601 61 and 47/48 kD.
Ig in the sera of the eight patients classified to stage I11 (patients 14-21) were found to react with eight to 13 polypeptides, IgM with as many as five, and IgG with six to 12. No additional polypeptides beside those also seen in stages I and I1 were visualized. Binding of IgM was detectable in all sera except in one from a patient with arthritis, but it involved a smaller number of proteins than in stage I1 (mean 2.5 bands per serum with reacting IgM versus 5.7). IgG, however, reacted with substantially mare prateins than in stage I T (mean 10 versus 2.8). In stage 111 every scrum bound IgG to thc four proteins 83, 6016 1, 41, and 29 kD, a feature not found in stages I and 11. Moreover, in stage I11 all scra but one contained IgG binding to the 58-kD polypeptide which was not visualized by stage I1 sera. Furthermore, antibodies binding to thc 60161-kD protein were exclusivcly IgG. Anti-55-kD protein antibodies, commonly found in stages I and 11, wcrc exceptional. All patients with arthritis except one differed from thosc with ACA by the absence of antibodies binding to thc 75-kD polypeptide and all except two by the lack of Ig reacting with tlic 1711 8-kD protein. Among the patients with arthritis one (patient 16) diffcred markedly from the others by absent antibodies reacting with thc 58-, 47148-, 41-, and 22-kD polypeptides.
No reactions were seen with the sera from the five normal individuals and with the conjugatc alonc. The two syphilis sera showed weak reactions: one with IgG against the proteins 4 = stages of the disease and in part also between clinical settings within the same stage we find considerable variations in number and nature of polypeptides bound and of binding isotypes. The number of polypeptides detected in this study is similar (16, 17) or higher than in other reports (18) (19) (20) . This might be due to several causes.
I ) Technical differences-we did not add protease inhibitors during polypeptide separation by SDS-PAGE. Thus, insuficient breakdown of polypeptide dimers of B. burgdorferi might have resulted in supplementary or distinct bands (16) . In addition, we transferred the polypeptides from SDS to NC by a semidry horizontal electrophoretic method which was not applied in other similar studies and which might also influence the results. 2) The strains of B. burgdorferi used as antigen might influence the detection of polypeptides of different molecular weight.
3) The geographical areas might be populated by antigenically different B. burgdorferi strains, which would elicit divergent host responses.
4) Stages of Lyme disease in our patients are different, and we compare them. Previous authors included patients with the same clinical setting or patients progressing through different stages. All the polypeptides visualized in our analysis, however, correspond to proteins previously observed in electrophoreses of the B. burgdorferi strain B3 1 (2 1).
In our study, IgM is the predominant isotype in stage I and even more pronounced in stage 11, whereas in stage I11 the major isotype is IgG. False-positive results of IgM detection due to rheumatoid factor were ruled out. These findings are in agree-ment with previous results in adults with early Lyme disease (16, 19) . Inasmuch as we did not separate the isotypes before incubation of the sera, a competitive advantage of IgG over IgM in their binding to the polypeptide antigens cannot be excluded.
In our study with cross-sectional character, the scope of proteins bound by antibodies enlarged remarkably from stage I to stage 111. A similar finding was reported from a longitudinal analysis in adults progressing through the different stages of Lyme disease (18) . This appearance of new protein bands during the course of the illness suggests the persistence of B. burgdorferi within the host: the longer the bacterium is not eliminated, the more additional antigens, corresponding to protein bands, will be recognized by the host's immune system. Indeed, viable B. burgdorferi has been isolated from individuals with different clinical stages and settings of Lyme disease (2) .
We and others (16) have demonstrated that the binding of antibodies in stage I is not restricted to the 41-kD protein, which is associated to the borrelial flagellum (22) . This contrasts with findings in previous studies pointing out the ability of the 4 1-kD protein to suppress the immune response in early Lyme disease (1 8, 19 ). Furthermore, we have shown that patients with stage I may exhibit distinct antibody patterns, depending on their clinical setting: sera of patients with ECM recognize the proteins 3 1 and 29 kD, but patients with headaches do not. The antibody pattern of the only child with meningitis is similar to that of reported patients (17, 20) . Despite divergences between the patients with different manifestations, we cannot discriminate a clear-cut antibody pattern for each setting in stage 11. In stage 111, however, we find serologic patterns in children with arthritis which differ from those in patients with ACA. The antibody panels in children with arthritis are analogous to those of the few reported patients with the same setting (18) . In contrast to a previous study. (22) , our patients with ACA recognized more polypeptides than patients with arthritis.
In our study, none of the children with stage I11 had previous ECM or neurologic involvement and none with stage I1 had a history of ECM, and this is consistent with recent reports in the literature. Thus, the question arises, whether the classification of Lyme disease into three stages is justified. Applying this classification, we and others (1 8) find, as already mentioned, an increase in the number of proteins recognized from stage I to 111. This has been explained by the different duration of persistence of B. burgdorferi within the host. Therefore, classification into three stages seems appropriate. But taking into account the patients with an atypical history, another question arises, i.e. whether the clinical expression of Lyme disease is determined by properties of the infecting B. burgdorferi strain with particular antigenic components, or rather by the individual immune response of the host.
The clinical presentation of B. burgdorferi infection varies geographically. In northern Europe neurologic disorders and ACA predominate, whereas in the United States joint involvement seems to be more frequent. These observations could be explained by a hypothesis of different strains causing different diseases. In fact, the polypeptides of Scandinavian and North American B. burgdorferi isolates are not identical (23) , and strains from central Europe have recently been described in correlation with diverse clinical manifestations (24) .
However, it is still obscure why some individuals overcome infection with B. burgdorferi without symptoms, and why in some patients Lyme disease is restricted, e.g. to ECM, and why in others, with or without a typical history, it develops into a chronic disorder. Individual proneness of the host to such different evolution, analogous to HLA-B27-associated arthritis, could provide an explanation. In fact, the HLA-phenotype DR2 has been reported with significant preponderance in patients with chronic Lyme disease (25, 26) .
In patients lacking the typical history of tick bite and/or of ECM, the diagnosis of Lyme disease has to rely on serologic findings. Antibodies against B. burgdorferi, however, may also be detected in asymptomatic individuals. In endemic areas up to 9% of the population were found to be seropositive (27) . So far, no definite laboratory test differentiates between specific IgG in active disease from the asymptomatic antibody response. Such a distinction would be of therapeutic relevance to avoid unnecessary antibiotic treatment.
Indirect indicators for recent or actual infection are seroconversion or presence of specific IgM. But early seroconversion in Lyme disease is rarely detected because first symptoms may considerably lag behind the infection. Moreover, detection of IgM by IFA or ELISA test is enigmatic (6) . Immunoblotting could facilitate the distinction between active infection and serological scar: first by detection of specific IgM and second by visualization of the complex pattern of antibodies binding to many polypeptides. Several investigators (1 6, 18) have stressed the superiority over other serologic methods of immunoblotting in detection of IgM. All these data are quite suggestive for the value of antigen-antibody patterns in close correlation with the clinical evolution.
